GYRE THERAPEUTICS, INC. GYRE
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
8.71
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $116.6M | $9.9M | — | -$180,000 | $142.3M |
| 2024 | $105.8M | $17.9M | $101.9M | -$6.0M | $98.4M |
| 2023 | $113.5M | -$85.5M | $108.8M | $17.4M | $13.9M |
| 2022 | $102.3M | $4.3M | $97.5M | $5.7M | $72.2M |
| 2021 | $7.3M | -$87.9M | — | -$84.6M | $59.5M |
| 2020 | $20.9M | -$56.2M | — | — | $76.1M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Ye Weiguo | Chief Operating Officer | 2026-06-18 | Option exercise | 3,000 | $0.75 |
| Ye Weiguo | Chief Operating Officer | 2026-06-18 | Sell | 3,000 | $6.35 |
| Ye Weiguo | Chief Operating Officer | 2026-06-11 | Sell | 2,800 | $6.17 |
| Ye Weiguo | Chief Operating Officer | 2026-06-11 | Option exercise | 2,800 | $0.75 |
| Ye Weiguo | Chief Operating Officer | 2026-06-10 | Option exercise | 5,000 | $0.75 |
| Ye Weiguo | Chief Operating Officer | 2026-06-10 | Sell | 5,000 | $6.24 |
| Ye Weiguo | Chief Operating Officer | 2026-06-10 | Option exercise | 6,418 | $0.75 |
| Ye Weiguo | Chief Operating Officer | 2026-06-10 | Sell | 6,418 | $6.21 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 8.71 (safe)
- Working capital / assets 0.506
- Retained earnings / assets -0.412
- EBIT / assets 0.069
- Equity / liabilities 5.966
Source: SEC EDGAR filings · CIK 0001124105 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.